Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin for Post-COVID-19 Olfactory and Gustatory Dysfunction
NCT06208540Phase 4Completed
- Start
- Aug 2021
- Primary completion
- Apr 2024
- Modality
- Native Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of cerebrolysin in anosmia, Ageusia, Hyposmia and 1 more (2 arms). Primary endpoints: Subjective evaluation and Objective evaluation. Started Aug 2021; status: completed.
02
Drugs
cerebrolysin
03
Conditions
anosmiaAgeusiaHyposmiahypogeusia
Beyond the preview
Go deeper on NCT06208540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208540.